AKBA · Akebia Therapeutics, Inc.
$0.91
-0.05 (-5.42%)
At close · Aug 26
Market Cap
$249.56M
Shares
277.11M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.91
Open$0.96
Day$0.88–0.96
52W close$0.84–3.17
Avg vol 30d5.2M
Short int21.4M · 7.7% float · 3.5d
Short vol69%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−21%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−24%
trailing
YTD return
−44%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.71% of float · ▲ +11.4% MoM · 3.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
170 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
EPS growth
+94%
Y/Y
Free cash flow
$67.7M
Balance sheet
$136.6M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2023
Annual net product revenue
· annual
$175M – $180M
Prior guidance
period ended
· from the 8-K filed Jan 12, 2026
Vafseo net product revenue
· Q4 2025
$5M – $6M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.71% of float · ▲ +11.4% MoM · 3.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
170 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 3%
Range high $3
vs 200-day avg -32%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| patients active on Vafseo | 10,500 | Q2 2026 | — |
| Total number of prescribers | 1,200 | Q2 2026 | — |
|
|
|||
| First refill adherence rates | 86% | Q1 2026 | — |
|
|
|||
| Patient access to Vafseo therapy | 290,000 | Q4 FY2025 | — |
| Patient demand | $11M | Q4 FY2025 | — |
| patients on dialysis with prescribing access for Vafseo | 275,000 | 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKBA
this stock
Akebia Therapeutics, Inc.
|
$249.56M | -43.7% | +47.5% | — | 7.7% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.22B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.94B | +2.3% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.77B | +0.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKBA | +2.4% | -28.1% | -23.8% | -31.3% | -43.7% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +2.8% | -33.1% | -36.3% | -33.9% | -56.0% |
Key facts
CIK
1517022
CUSIP
00972D105
13F (30d)
144 filings
144 filers
Visit website
Investor relations